A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
Wu‐tong Ju(Shanghai Jiao Tong University), Lai‐ping Zhong(National Clinical Research Center for Digestive Diseases)
Cited by 119
Related Papers
Overcoming chemotherapy resistance using pH-sensitive hollow MnO2 nanoshells that target the hypoxic tumor microenvironment of metastasized oral squamous cell carcinoma
|Journal of Nanobiotechnology|2021|56
Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma
|Journal of Experimental & Clinical Cancer Research|2017|35